- Vaxcyte, Inc. announced a new agreement with Thermo Fisher Scientific Inc. to expand fill-finish commercial manufacturing for its pneumococcal conjugate vaccines (PCVs) in the United States.
- The collaboration, valued at up to $1 billion, will provide custom commercial capacity at Thermo Fisher’s Greenville, North Carolina facility as part of Vaxcyte’s long-term U.S. supply strategy.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, has entered into a new agreement with Thermo Fisher Scientific Inc. to expand its fill-finish commercial manufacturing capacity for broad-spectrum pneumococcal conjugate vaccines (PCVs) in the United States.
The agreement forms part of Vaxcyte’s long-term U.S. commercial supply strategy and represents a manufacturing commitment of up to $1 billion. Under the arrangement, Thermo Fisher will provide custom commercial fill-finish services for Vaxcyte’s PCVs at its facility in Greenville, North Carolina.
Through this partnership, Vaxcyte aims to enhance its domestic biomanufacturing footprint and strengthen its end-to-end supply chain ahead of future commercial production.
“The decision to significantly expand our fill-finish manufacturing capacity in the United States represents an effort to expand our end-to-end supply strategy and align with the increasing focus on domestic biomanufacturing.”
Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte
